[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse EEF1A2

Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00009 Elongation factor Tu GTP binding domain
PF03144 Elongation factor Tu domain 2
PF03143 Elongation factor Tu C-terminal domain
Function

This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.

> Gene Ontology
 
Biological Process GO:0006414 translational elongation
GO:0006914 autophagy
GO:0010035 response to inorganic substance
GO:0010506 regulation of autophagy
GO:0019216 regulation of lipid metabolic process
GO:0033674 positive regulation of kinase activity
GO:0043550 regulation of lipid kinase activity
GO:0045834 positive regulation of lipid metabolic process
GO:0051602 response to electrical stimulus
GO:0061684 chaperone-mediated autophagy
GO:0090218 positive regulation of lipid kinase activity
GO:1904714 regulation of chaperone-mediated autophagy
Molecular Function GO:0003746 translation elongation factor activity
GO:0003924 GTPase activity
GO:0005525 GTP binding
GO:0008135 translation factor activity, RNA binding
GO:0019001 guanyl nucleotide binding
GO:0032561 guanyl ribonucleotide binding
Cellular Component GO:0005765 lysosomal membrane
GO:0005853 eukaryotic translation elongation factor 1 complex
GO:0043025 neuronal cell body
GO:0043209 myelin sheath
GO:0044297 cell body
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:0098574 cytoplasmic side of lysosomal membrane
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa03013 RNA transport
Reactome R-HSA-156842: Eukaryotic Translation Elongation
R-HSA-74160: Gene Expression
R-HSA-392499: Metabolism of proteins
R-HSA-72766: Translation
Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EEF1A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between EEF1A2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24068664Bladder CarcinomaEssential for immunotherapyIn vitro studies were conducted to determine the interaction of BCG with high-grade bladder cancer cell line overexpressing sTn. sTn or s6T expression was associated with BCG response (P=0.024; P<0.0001) and with increased recurrence-free survival (P=0.001). Multivariate analyses showed that sTn and/or s6T were independent predictive markers of recurrence after BCG immunotherapy (HR=0.296; (0.148-0.594); P=0.001). Our data strongly suggest that BCG immunotherapy is efficient against sTn- and s6T-positive tumours.
Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EEF1A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EEF1A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1230.904
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3240.859
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0250.987
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.760.376
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.5170.356
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2010.916
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2050.831
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.010.994
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1380.922
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1570.928
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.7680.436
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6860.0843
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EEF1A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EEF1A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EEF1A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EEF1A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EEF1A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EEF1A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EEF1A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEEF1A2
Nameeukaryotic translation elongation factor 1 alpha 2
Aliases STNL; STN; statin-like; statin; EF-1-alpha-2; EIEE33; MRD38; eukaryotic elongation factor 1 A-2; statin-S1; ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EEF1A2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.